Congenital Pediatric Disorders
Conditions
Keywords
Congenital Pediatric Disorders, Umbilical Cord Blood Transplant, Congenital Abnormalities, Cord Blood Stem Cell Transplantation, Busulfan, Cytoxan, Cyclophosphamide, Fludarabine
Brief summary
The purpose of this study is to determine the safety and effectiveness of Umbilical Cord Blood Transplant (UCBT) to treat the patient's disease, and to see if this treatment can decrease the incidence of GVHD. This study is for patients that were born with a disease that affects their body's metabolism or immune system. The doctor plans to treat the patient for this illness with a stem cell transplant. While improved medical care has allowed many people with these diseases to live longer, the only way to truly cure the diseases is by means of a stem cell transplant from a donor who does not have the disease. A stem cell transplant will replace sick cells with new healthy donor cells. Stem cells grow into different types of blood cells that people need, including red blood cells, white blood cells, and platelets. In a stem cell transplant, the patients own stem cells would be killed by chemotherapy drug and then replaced by stem cells from the donor. Stem cells can be collected from the bone marrow, peripheral blood or umbilical cords. In this study, umbilical cords will be the source of the stem cells. Currently, large inventories of umbilical cord blood units are available in public banks for transplantation in those lacking bone marrow donors. UCB transplants offer several advantages over adult bone marrow or peripheral blood stem cell transplants, including: 1. Rapid availability, 2. Absence of donor risk, 3. Low risk of transmissible infectious diseases, 4. Low risk of acute GvHD (as compared to recipients of unrelated donor marrow and peripheral blood cells). The two main causes of death after umbilical cord blood transplantation for disorders for these kinds of patients, are graft failure and infection. In this study we are trying to address these two problems by using different drugs to prepare patients for the transplant. To help improve engraftment (cells begin to grow), we will include the drug Fludarabine to the usually used Busulfan and Cytoxan that the study patients will receive before their transplant. We will try to decrease the chance of developing graft-versus-host disease (GvHD) by using Cyclosporin A (CSA) and Mycophenolate Mofetil (MMF), instead of Anti-Thymocyte Globulin (ATG) which is normally used.
Detailed description
Patients will be examined to make sure that they meet the requirements of this study. There will be tests of the heart and of the lungs. X-rays will be taken of the lungs and other organs, depending on the disease. An MRI and consultations with different specialists will also be conducted. Patients also must have a negative pregnancy test before entering this study if they are a woman of childbearing potential. The blood will be tested for viruses and to look at the functioning of the liver and kidneys. The examination also includes HIV testing. If the patient has HIV, they will not be able to be treated on this protocol. After we have determined that the patient is eligible for treatment on this study and a suitable UCB stem donor has been found, they will have a central line placed. After placement of the central line, the following chemotherapy will be given to after admission to the hospital: * 9 days before the infusion through 6 days before the infusion: Busulfan every 6 hours for 16 total doses. * 5 days before the infusion through 2 days before the infusion: Cytoxan given daily for 4 days over 2 hours. (It can be given over 1 to 4 hours if needed as decided by the physician). Mesna will be given per standards. * 4 days before the infusion through 1 day before the infusion: Fludarabine given daily for 4 days over 1 hour. Stem cell transplant (infusion of the UCB stem cells) - defined as Day 0 of the treatment. All other numbered days relate to this infusion date. For example, Day 1 is the first day after the stem cell transplant. Standard Therapy: Phenytoin will be given according to the standards of the TCH formulary. Cyclosporin A (CSA) will be given starting 2 days prior to the stem cell infusion. It will be given daily over 2 hours every 12 hours, and then tapered if no GvHD is present. Administration of Mycophenolate Mofetil (MMF) will start on the day the stem cell infusion is completed, and will continue daily for 45 days unless the patient develops GvHD. Intravenous Immunoglobulins (IVIG) will be given as per CAGT SOP for infections prophylaxis. Granulocyte Colony-Stimulating Factor (GCSF) will be given daily starting at Day +7 until ANC is greater than 2,500 for three consecutive days. Study Evaluation: Patients will have various study evaluations, including blood samples, before and after the transplant. Follow-Up: After year 1, the patients will be asked to return to the clinic once a year for consultations. These consultations with specialists will be similar to the ones the patients had before their transplant.
Interventions
DRUGBusulfan
Day -9, -8, -7 and -6 Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses.
DRUGCytoxan
(50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
DRUGFludarabine
40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
PROCEDURECord Blood Stem Cell Infusion
The cord blood stem cells will be infused on Day 0.
Sponsors
Center for Cell and Gene Therapy, Baylor College of Medicine
Baylor College of Medicine
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
No minimum to 17 Years
Healthy volunteers
No
Inclusion criteria
* Patients less than 18 years of age. * Patients with a congenital or acquired immunologic, hematological, or metabolic pediatric disease (including SCID) in which stem cell transplantation has been beneficial. * Related or Unrelated Umbilical Cord Blood Unit with 0-1 antigen mismatch, 5-6 HLA- A and B (at low to intermediate resolution) and DRB1 (at high resolution). * Total cryopreserved HSC graft cell dose must be 5 x 10\^7 or greater nucleated cells per kilogram recipient body weight. * Lansky/Karnofsky scores 60 or greater. * Patient has DLCO \> 50% predicted or FEV1 \> 50%, if applicable. * Written informed consent and/or signed assent line from patient, parent or guardian.
Exclusion criteria
* Patients with uncontrolled infections as assessed by the principal investigator only. For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to starting conditioning. For fungal infections patients must be receiving definitive systemic antifungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection. * Severe renal disease (creatinine \> 3X normal for age). * Severe hepatic disease (direct bilirubin \> 3 mg/dL or SGOT \> 500). * Patients with symptomatic cardiac failure unrelieved by medical therapy or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction \< 20%). * HIV positive.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival at 100 Days After Umbilical Cord Blood Transplant in Pediatric Patients. | 100 days | To determine the overall survival rate at 100 days after umbilical cord blood transplant in pediatric patients with myeloid hematological malignancies. |
| Overall Survival at 1 Year After Umbilical Cord Blood Transplant in Pediatric Patients. | 1 year | To determine the overall survival rate at 1 year after umbilical cord blood transplant in pediatric patients with myeloid hematological malignancies. |
| Overall Survival at 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients. | 3 years | To determine the overall survival rate at 3 years after umbilical cord blood transplant in pediatric patients with myeloid hematological malignancies. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Donor Engraftment After Transplant. | 100 days, 6 months and 12 months | To evaluate donor engraftment at 100 days, 6 and 12 months after transplant. |
| Number of Participants With Platelet Engraftment | Day 42 | Achievement of untransfused platelet count \> 20 x 10\^9/L on three consecutive days |
| Number of Participants With Neutrophil Engraftment | Day 42 | Achievement of absolute neutrophil count \> 0.5 x 10\^9/L on three consecutive days |
| Incidence of Severe Grade III-IV Acute GvHD at Day 100. | Day 100 | Number of participants with acute GVHD graded by the method of Przepiorka et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD. |
| Number of Participants With Chronic GvHD | 1 year | Number of participants with chronic GVHD graded by the method of Przepiorka et al, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3. |
Countries
United States
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Umbilical Cord Blood Transplant Treatment Plan Busulfan, Cytoxan, Fludarabine, Cord Blood Stem Cell Infusion
Busulfan: Day -9, -8, -7 and -6
Patients less than or equal to 12 kg: 1.1 mg/kg/dose IV every 6 hours for 16 doses total; patients \>12 kg: 0.8 mg/kg/dose IV every 6 hours for 16 doses.
Cytoxan: (50 mg/kg/dose) will be given IV on Days -5, - 4, -3, and -2 over 2 hours (can be given over 1 to 4 hours as determined by the treating physician). The total dose to be given over 4 days is 200 mg/kg.
Fludarabine: 40 mg/m2/day IV over 1 hour for patients greater than 10 kg, or 1.3 mg/kg/day for patients less than or equal to 10 kg.
Cord Blood Stem Cell Infusion: The cord blood stem cells will be infused on Day 0. | 38 |
| Total | 38 |
Withdrawals & dropouts
| Period | Reason | FG000 |
|---|---|---|
| Overall Study | Death | 6 |
| Overall Study | Lost to Follow-up | 3 |
| Overall Study | Possible undiagnosed AML at study entry | 1 |
Baseline characteristics
| Characteristic | Umbilical Cord Blood Transplant Treatment Plan |
|---|---|
| Age, Continuous | 5 months |
| Ethnicity (NIH/OMB) Hispanic or Latino | 20 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 18 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 1 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 35 Participants |
| Sex: Female, Male Female | 15 Participants |
| Sex: Female, Male Male | 23 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 6 / 40 |
| other Total, other adverse events | 25 / 40 |
| serious Total, serious adverse events | 27 / 40 |
Outcome results
Primary
Overall Survival at 100 Days After Umbilical Cord Blood Transplant in Pediatric Patients.
To determine the overall survival rate at 100 days after umbilical cord blood transplant in pediatric patients with myeloid hematological malignancies.
Time frame: 100 days
Population: The analysis included 38 evaluable participants who completed conditioning and received transplants. Two participants were excluded from the analysis. One participant died before receiving transplant and the other was diagnosed with aplastic anemia without signs of malignancy at the time of enrollment, but later showed signs of MDS and progressed to AML, which made the participant not evaluable for this study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Umbilical Cord Blood Transplant Treatment Plan | Overall Survival at 100 Days After Umbilical Cord Blood Transplant in Pediatric Patients. | 0.947 probability of overall survival |
Primary
Overall Survival at 1 Year After Umbilical Cord Blood Transplant in Pediatric Patients.
To determine the overall survival rate at 1 year after umbilical cord blood transplant in pediatric patients with myeloid hematological malignancies.
Time frame: 1 year
Population: The analysis included 38 evaluable participants who completed conditioning and received transplants. Two participants were excluded from the analysis. One participant died before receiving transplant and the other was diagnosed with aplastic anemia without signs of malignancy at the time of enrollment, but later showed signs of MDS and progressed to AML, which made the participant not evaluable for this study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Umbilical Cord Blood Transplant Treatment Plan | Overall Survival at 1 Year After Umbilical Cord Blood Transplant in Pediatric Patients. | 0.868 probability of overall survival |
Primary
Overall Survival at 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients.
To determine the overall survival rate at 3 years after umbilical cord blood transplant in pediatric patients with myeloid hematological malignancies.
Time frame: 3 years
Population: The analysis included 38 evaluable participants who completed conditioning and received transplants. Two participants were excluded from the analysis. One participant died before receiving transplant and the other was diagnosed with aplastic anemia without signs of malignancy at the time of enrollment, but later showed signs of MDS and progressed to AML, which made the participant not evaluable for this study.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Umbilical Cord Blood Transplant Treatment Plan | Overall Survival at 3 Years After Umbilical Cord Blood Transplant in Pediatric Patients. | 0.868 probability of overall survival |
Secondary
Incidence of Severe Grade III-IV Acute GvHD at Day 100.
Number of participants with acute GVHD graded by the method of Przepiorka et al, which evaluates skin involvement, lower and upper GI, and liver function (bilirubin), each being graded in stages from 0 to 4, where 0 means no acute GVHD, and 4 is the highest stage of acute GVHD.
Time frame: Day 100
Population: The analysis included all participants who received transplants and were evaluable for acute GVHD. One participant was not evaluable due to possible undiagnosed AML at study entry and all other participants who received transplants were evaluable for acute GVHD if he/she engrafted and either completed 100 days observation after transplant or experienced acute GVHD.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Umbilical Cord Blood Transplant Treatment Plan | Incidence of Severe Grade III-IV Acute GvHD at Day 100. | 1 Participants |
Secondary
Number of Participants With Chronic GvHD
Number of participants with chronic GVHD graded by the method of Przepiorka et al, which evaluates skin, joints, oral, ocular, hepatic, esophagus, GI, respiratory, platelet, and musculoskeletal involvement, in stages from 0 to 3.
Time frame: 1 year
Population: The analysis included all participants who received transplants and were evaluable for chronic GVHD. One participant was not evaluable due to possible undiagnosed AML at study entry and all other participants who received transplants were evaluable for chronic GVHD if he/she engrafted and survived or remained in the study for more than 101 days after transplant.
| Arm | Measure | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|
| Umbilical Cord Blood Transplant Treatment Plan | Number of Participants With Chronic GvHD | 1 Participants |
Secondary
Number of Participants With Donor Engraftment After Transplant.
To evaluate donor engraftment at 100 days, 6 and 12 months after transplant.
Time frame: 100 days, 6 months and 12 months
Population: The analysis included all participants who underwent transplant and were evaluable at the time of assessments. One participant was not evaluable due to possible undiagnosed AML at study entry.
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Umbilical Cord Blood Transplant Treatment Plan | Number of Participants With Donor Engraftment After Transplant. | 100 days | 36 Participants |
| Umbilical Cord Blood Transplant Treatment Plan | Number of Participants With Donor Engraftment After Transplant. | 6 months | 33 Participants |
| Umbilical Cord Blood Transplant Treatment Plan | Number of Participants With Donor Engraftment After Transplant. | 12 months | 33 Participants |
Secondary
Number of Participants With Neutrophil Engraftment
Achievement of absolute neutrophil count \> 0.5 x 10\^9/L on three consecutive days
Time frame: Day 42
Population: The analysis included 37 evaluable participants who completed conditioning, received transplants and were alive on day 42. Three participants were excluded from the analysis. One participant died before receiving transplant, one was not evaluable due to possible undiagnosed AML at study entry, and one died on day 31 after transplant.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Umbilical Cord Blood Transplant Treatment Plan | Number of Participants With Neutrophil Engraftment | Engrafted | 37 Participants |
| Umbilical Cord Blood Transplant Treatment Plan | Number of Participants With Neutrophil Engraftment | Not engrafted | 0 Participants |
Secondary
Number of Participants With Platelet Engraftment
Achievement of untransfused platelet count \> 20 x 10\^9/L on three consecutive days
Time frame: Day 42
Population: The analysis included 37 evaluable participants who completed conditioning, received transplants and were alive on day 42. Three participants were excluded from the analysis. One participant died before receiving transplant, one was not evaluable due to possible undiagnosed AML at study entry, and one died on day 31 after transplant.
| Arm | Measure | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Umbilical Cord Blood Transplant Treatment Plan | Number of Participants With Platelet Engraftment | Engrafted | 17 Participants |
| Umbilical Cord Blood Transplant Treatment Plan | Number of Participants With Platelet Engraftment | Not engrafted | 20 Participants |